History

Close timeline
Click to view timeline

20182018

Evotec achieves second milestone in diabetes alliance with Sanofi

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Evotec forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center

Evotec and Celgene expand iPSC collaboration to include additional cell lines

Evotec and Celgene enter into strategic oncology partnership

Evotec and Bayer advance third endometriosis programme into Phase I clinical development

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

20172017

Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim

Evotec joins forces with academic leaders to accelerate drug discovery in kidney diseases and build NEPLEX

Evotec achieves first milestone in neurodegeneration alliance with Celgene

Evotec invests in Exscientia to advance AI-driven drug discovery

Evotec and MaRS Innovation establish LAB150 in Toronto

European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan

Evotec acquires Aptuit

Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance

Evotec announces strategic investment in Facio Therapies to support development of novel FSHD therapy

Evotec joins NURTuRE consortium to mine unique kidney disease patient biobank

Evotec achieves first milestone in Diabetes alliance (TargetBCD) with Sanofi

Novo A/S becomes new long-term strategic shareholder in Evotec

Evotec and Eternygen to develop novel metabolic disease therapy, Evotec participate in Eternygen's Series A funding

20162016

Multi-year drug discovery collaboration for neurodegenerative diseases with Celgene based on Evotec`s iPSC platform

Evotec acquired Cyprotex, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK

Evotec and Oxford University create novel Partnership called 'LAB282'

Evotec and Carrick Therapeutics build strategic alliance, Evotec contributes to funding round

Evotec enters into strategic multi-target alliance with C4X Discovery

Evotec and Bayer partner to develop new treatments to fight kidney diseases

Start of first Phase I within Endometriosis alliance with Bayer

Evotec and Ellersbrook join forces to accelerate development of TargetNASH

Evotec extends integrated drug discovery alliance with Genentech

Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics (TargetBiSM)

Position cemented as the world leader in outsourced compound management through new agreements with UCB and Pierre Fabre

Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH'

Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research (TargetaSN)

20152015

Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer

Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis (TargetFibrosis)

Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease

Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies (TargetImmuniT)

Sanofi and Evotec align forces to develop next generation therapies in diabetes (TargetBCD)

Evotec's partner Roche announced that Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer's disease failed to demonstrate benefit on the primary endpoint

Evotec and Sanofi sign definitive agreement for major mulit-component strategic alliance and acquires Sanofi's scientific operations and related employees at Toulouse site

Second Genome and Evotec to collaborate in microbiome discovery and development (TargetMB)

Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration

20142014

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease

Termination of the development of DiaPep277® (one of Evotec's advanced partnered pipeline projects) by Hyperion Therapeutics, Inc.

Twenty three milestones achieved as part of the collaboration with Boehringer Ingelheim

Evotec establishes an anti-infectives platform with the acquisition of Euprotec Ltd

Evotec acquires Bionamics GmbH to accelerate EVT Innovate strategy

20132013

Evotec and Yale University to collaborate on cancer therapy (TargetDBR)

Evotec announces TargetAD collaboration with Johnson & Johnson Innovation to identify and develop novel Alzheimer's disease therapies

Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways (TargetEEM)

Evotec and Harvard Stem Cell Institute form CureMN collaboration to advance ALS research

Evotec and Harvard University to collaborate on development of new class of antibacterials (TargetPGB)

Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology (TargetKDM)

Evotec extends drug discovery alliance with Genentech

Evotec acquires Cell Culture Service GmbH

Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy (TargetImmuniT)

20122012

Evotec partners its EVT100 series with Janssen Pharmaceuticals

Evotec partners with Haplogen to develop drugs for infectious diseases (TargetPicV)

Evotec extends ongoing collaboration with CHDI Foundation

Evotec and Bayer enter into long-term, multi-target alliance to fight Endometriosis

NIH awards major contract to Evotec to manage and operate a small molecule repository

Evotec and Harvard University enter first academic bridge alliance with Janssen Pharmaceuticals (CureBeta)

Evotec grants exclusive rights on EVT401 in China to CONBA Pharmaceutical

Evotec Action Plan 2016 – Innovation Efficiency

Evotec and Harvard University expand strategic alliance into Kidney Disease (CureNephron)

20112011

Evotec and Roche sign an agreement to develop compound (EVT302) against Alzheimer’s disease

Start of multi-target collaboration with UCB in neurodegenerative and neurological diseases and in the field of immunology

Evotec and Roche to jointly develop biomarkers in oncology

Evotec acquires compound management business from Galapagos and further strengthens its innovation offering

Evotec and Roche decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT101

Evotec acquires Kinaxo, expanding its drug discovery platform with cutting-edge technologies

Evotec establishes research collaboration with Harvard University and the Howard Hughes Medical Institute in diabetes research (CureBeta)

20102010

Evotec entered into a licence and collaboration agreement with MedImmune in the diabetes therapeutic area with a particular focus on the regeneration of insulin producing beta cells

Evotec licenses Phase II insomnia (EVT201) candidate to JingXin Pharma for development in China

Evotec is adding a core capability in metabolic disease biology by acquiring DeveloGen

Start of Phase II with EVT101 (Treatment-resistant depression) in collaboration with Roche

Start of integrated long-term drug discovery alliance with Genentech

Extension of CHDI collaboration

20092009

TecDAX re-entry/Evotec voluntarily delists from NASDAQ

Evotec and Boehringer Ingelheim extend and broaden research collaboration

Start of Phase I with EVT103 (Treatment-resistant depression) in collaboration with Roche

Evotec accelerates growth strategy of its discovery alliance business with acquisition of Indian RSIPL

Successful Completion of first Phase I Study with EVT401 (P2X7)

Evotec acquires Zebrafish Screening Operations of Summit Corporation

Evotec Restructures and Implements "Evotec 2012 - Action Plan to Focus and Grow"

Evotec and Roche to develop EVT101 for treatment-resistant depression

20082008

Three-year drug discovery collaboration with Novartis

Start Phase I with P2X7 Antagonist (EVT401) in inflammatory disease

Evotec completes acquisition of Renovis, NASDAQ-Listing

20072007

Evotec sells its Chemical Development Business to Aptuit

Evotec and Research Support International Limited form Evotec-RSIL Ltd, a Joint Venture in India for the design, synthesis, management and commercialisation of compound libraries

Positive results in two Phase II trials with EVT201 in insomnia

20062006

Evotec sells Evotec Technologies to PerkinElmer

Start of multi-year drug discovery alliance with CHDI on Huntington disease

Forming a global alliance with Roche to jointly discover and develop compounds in the area of CNS

Extension of global medicinal chemistry agreement and medicinal chemistry collaboration in oncology with Roche

Successful completetion of Phase I for potential Alzheimer's Disease treatment, EVT101

Further expansion and extension of Boehringer Ingelheim drug discovery collaboration

Evotec in-licenses two Phase I MAO-B inhibitor from Roche with disease modifying potential in Alzheimer's Disease

20052005

Capital increase, EUR 28.4 m

Extension of medicinal chemistry agreement with Roche

20042004

Start of multi-year, multi-target drug discovery alliance with Boehringer Ingelheim

Strategic global medicinal chemistry agreement with Roche

Evotec Neurosciences to licence NMDA receptor NR2B subunit selective antagonists from Roche

20032003

Evotec Neurosciences and Takeda enter into a four-year collaboration to identify novel Alzheimer's disease targets

20022002

Spinning off its technology development business into its subsidiary Evotec Technologies

Extension of Discovery Chemistry Agreement with Roche

20012001

Initial service collaborations with Eli Lilly, Merck, Novartis and Roche

20002000

Merge with Oxford Asymmetry International plc, form Evotec OAI AG, to become the leader in the discovery and development of novel small molecule drugs

Successful market introduction of EVOscreen®

19991999

In November, Evotec BioSystems AG goes public

Establishes Evotec Neurosciences GmbH in Hamburg

19981998

Raising DM 46 m (EUR 23.5 m), the largest private placements seen in the European biotech sector

19961996

Collaborations with Novartis and SmithKlineBeecham to develop EVOscreen® (High-Throughput Screening System)

19931993

Evotec BioSystems GmbH was founded in Hamburg, Germany. Among the founders were Nobel Laureate Professor Manfred Eigen, Dr Karsten Henco, Dr Ulrich Aldag, Dr Freimut Leidenberger, Dr Heinrich Schulte, Professor Rudolf Rigler and Dr Charles Weissmann

TOP